Abstract: A composition for treating pain includes an antibody or antibody fragment that specifically binds to a receptor involved in pain. In some embodiments, the receptor is a P2X family receptor such as, for example, P2X4. In some embodiments, the antibody includes a detectable marker. In some of these embodiments, the detectable marker includes a fluorescent tag. The composition may be used to treat acute or chronic pain in a subject. Generally, the methods includes administering to the subject a composition that includes an antibody or antibody fragment that specifically binds to a receptor involved in pain. The non-opioid pain relief composition can reverse pain related mechanical, cold, anxiety-like, and depression-like behaviors in neuropathic pain and chemotoxic nerve injury models.

Abstract: A pharmaceutical composition generally includes a therapeutic antibody, or fragment thereof, and a pharmaceutically acceptable carrier. The therapeutic antibody specifically binds to a target peptide that mediates pain in a subject. The composition may be administered to a subject experiencing pain to at least partially alleviate the pain.

Abstract: In one aspect, a fusion antibody specifically binds to a C. difficile virulence toxin. In some embodiments, the C. difficile virulence toxin can include TcdA or TcdB. In some embodiments, the fusion antibody can include a first antibody moiety and a second antibody moiety. The first antibody moiety can include at least a fragment of a first antibody, and the second antibody moiety can include at least a fragment of a second antibody. In another aspect, a recombinant cell expresses the fusion antibody. In another aspect, a recombinant cell has activity that can be modulated by growing the recombinant cell in medium that includes cellobiose. Generally, the recombinant cell includes a heterologous polynucleotide that includes a promoter operably linked to a heterologous coding region, wherein the expression from the promoter is modulated when the recombinant cell is grown in culture medium that comprises cellobiose compared to when the recombinant cell is grown in culture medium that comprises glucose.

Abstract: Embodiments of the present invention provide for the facile generation of a stable recombinant fusion polypeptides with intrinsic fluorescent properties. The recombinant antibodies may be suitable for qualitative and/or quantitative immunofluorescence analysis. Generally, the fluorescent polypeptides include a fluorescent domain comprising a C-terminus and an N-terminus; a first antibody domain covalently linked to the C-terminus; and a second antibody domain covalently linked to the N-terminus.

Abstract: Embodiments of the present invention provide for the facile generation of a stable recombinant fusion polypeptides with intrinsic fluorescent properties. The recombinant antibodies may be suitable for qualitative and/or quantitative immunofluorescence analysis. Generally, the fluorescent polypeptides include a fluorescent domain comprising a C-terminus and an N-terminus; a first antibody domain covalently linked to the C-terminus; and a second antibody domain covalently linked to the N-terminus.

Abstract: Provided herein is an extremophile green alga designated as Scenedesmus species Novo, from Jemez warm water springs, New Mexico. Sequencing 18S rDNA confirmed the alga as a new species. It is capable of producing high levels of microalgal biomass in wastewater under harsh ambient climatic conditions, and of yielding high levels of lipids and carotenes. Cultures in TAP medium at 24±1° C. at continuous light (132-148 ?mol photons m?2s?1) attained peak biomass levels 27.4×106 cells ml?1, 49.11 ?g ml?1 chlorophyll ?, 24.93 ?g ml?1 carotene on the seventh day and a division rate of 0.54 day?1. High levels of biomass were sustained in sterilized and unsterilized municipal wastewater, enriched with 1% TAP nutrients or unenriched. The microalga is useful in the production of biofuels, fertilizers, dietary nutrients, pharmaceuticals, polymers, biofilters to remove nutrients and other pollutants from wastewaters, in space technology, and laboratory research systems.

Abstract: Embodiments of the present invention provide for the facile generation of a stable recombinant fusion polypeptides with intrinsic fluorescent properties. The recombinant antibodies may be suitable for qualitative and/or quantitative immunofluorescence analysis. Generally, the fluorescent polypeptides include a fluorescent domain comprising a C-terminus and an N-terminus; a first antibody domain covalently linked to the C-terminus; and a second antibody domain covalently linked to the N-terminus.

Abstract: Embodiments of the present invention provide for the facile generation of a stable recombinant fusion polypeptides with intrinsic fluorescent properties. The recombinant antibodies may be suitable for qualitative and/or quantitative immunofluorescence analysis. Generally, the fluorescent polypeptides include a fluorescent domain comprising a C-terminus and an N-terminus; a first antibody domain covalently linked to the C-terminus; and a second antibody domain covalently linked to the N-terminus.

Abstract: Embodiments of the present invention provide for the facile generation of a stable recombinant fusion polypeptides with intrinsic fluorescent properties. The recombinant antibodies may be suitable for qualitative and/or quantitative immunofluorescence analysis. Generally, the fluorescent polypeptides include a fluorescent domain comprising a C-terminus and an N-terminus; a first antibody domain covalently linked to the C-terminus; and a second antibody domain covalently linked to the N-terminus.